NEU neuren pharmaceuticals limited

Acadia, page-634

  1. 2,582 Posts.
    lightbulb Created with Sketch. 746
    Has anyone given a crack at estimating the Daybue revenues for Q2?

    Guidance has implied we should see about 15% QoQ growth averaged across these periods. I feel that we'll see a slightly larger increase QoQ compared to Q1 due to it being so weak, and then it averaging out whilst still being fairly backended.

    Here's my attempt which is conservative and only reaching the lower end of the guidance.

    Q1: 75.9
    Q2: 88.0 (+15%)
    Q3: 100m (+13.63%)
    Q4: 110m (+10%)
    Total: $373m USD

    This only assumes an average QoQ of 6.5% when you smooth out the bumps. That's still 25% annual growth, though and this is only North America.

    I am hopeful for this scenario instead. (Midpoint)

    Q1: 75.9
    Q2: 91 (+19%)
    Q3: 108 (+18%)
    Q4: 125 (+15%~)
    Total: 400m~ USD

    With Canada coming online I suspect a 15% patient growth QoQ should be achievable is long term persistence is improving. That would give a ballpark of 640m USD for 2025 and approaching 1b~ in sales in 2026 with a lower growth rate in North America (5-10%) but new markets (EU) adding with an initial burst of growth, albeit with a lower price of drug (unknown)

 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$14.57
Change
-0.040(0.27%)
Mkt cap ! $1.813B
Open High Low Value Volume
$14.94 $15.19 $14.51 $8.165M 551.5K

Buyers (Bids)

No. Vol. Price($)
1 2735 $14.55
 

Sellers (Offers)

Price($) Vol. No.
$14.65 1396 1
View Market Depth
Last trade - 16.10pm 11/07/2025 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.